NOS2 and colitis: In line with these findings, MSC-EVs treatment significantly reduced activation of IL-7 and iNOS-signaling pathways in colon macrophages, resulting in attenuated production of TNF-α, IL-1β, IL-6 and increased secretion of IL-10, which led to the alleviation of colitis [28].